Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

Not yet recruiting

• Conditions: Merkel Cell Carcinoma of Skin

• Registration Number: NCT06780475
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Detailed Description

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Study Timeline

• Study First Submitted: 2025-01-13
• Study First Submitted QC: 2025-01-13
• Study First Posted: 2025-01-17
• Status Verified: 2025-03
• Study Start: 2025-03
• Last Update Submitted: 2025-03-17
• Last Update Posted: 2025-03-20
• Primary Completion: 2027-03
• Study Completion: 2027-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patients >= 18 years old;
• Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
• Informed for the study and no-opposed for participation;
• Affiliated with a social security scheme or in an equivalent situation.

Exclusion Criteria

• Patients ongoing another interventional clinical trial;
• Patients under guardianship or trusteeship;
• Pregnancy or breastfeed;
• Patients refusal.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anti-MCPyV functionality	Day 0 and Day 4	Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.

Trial Locations

Locations (1)

Dermato-oncology Department, Ambroise Paré Hospital, APHP; 🇫🇷 Boulogne-Billancourt, France